View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 08, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Caladrius Biosciences, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		8,912,602

Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 23,044,844	$ 7,076,651
Restricted cash	5,000,722	0
Marketable securities	36,324,936	0
Accounts receivable, net of allowances of $0 at June 30, 2017 and December 31, 2016, respectively	335,646	138,774
Prepaid and other current assets	5,706,396	1,900,493
Current assets related to discontinued operations	0	15,533,043
Total current assets	70,412,544	24,648,961
Property, plant and equipment, net	432,853	705,439
Other assets	1,402,463	1,582,209
Other assets related to discontinued operations	0	26,577,834
Total assets	72,247,860	53,514,442
Current Liabilities
Accounts payable	1,114,122	2,226,580
Accrued liabilities	12,408,604	2,659,433
Long-term debt, current	0	3,126,457
Notes payable, current	578,353	563,777
Due to PCT	450,315	1,681,594
Current liabilities related to discontinued operations	0	10,925,052
Total current liabilities	14,551,394	21,182,893
Notes payable	23,290	159,180
Long-term debt	0	2,524,897
Other long-term liabilities	3,636,538	389,858
Liabilities related to discontinued operations	0	5,791,134
Total liabilities	18,211,222	30,047,962
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	0	19,400,000
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2017 and December 31, 2016	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 8,912,602 and 8,205,791 shares, at June 30, 2017 and December 31, 2016, respectively	8,913	8,206
Additional paid-in capital	430,606,930	410,372,049
Treasury stock, at cost; 11,080 shares at June 30, 2017 and December 31, 2016, respectively	(707,637)	(707,637)
Accumulated deficit	(375,429,627)	(404,788,809)
Accumulated other comprehensive income	(57,860)	0
Total Caladrius Biosciences, Inc. stockholders' equity	54,420,819	4,883,909
Noncontrolling interests	(384,181)	(817,429)
Total equity	54,036,638	4,066,480
Liabilities and Equity, Total	$ 72,247,860	$ 53,514,442

Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on accounts receivable	$ 0	$ 0
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	8,912,602	8,205,791
Common stock, shares, outstanding	8,912,602	8,205,791
Treasury stock (shares)	11,080	11,080

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating Expenses:
Research and development	$ 4,277,783	$ 4,488,603	$ 8,003,915	$ 10,537,452
General and administrative	3,432,534	2,917,221	6,138,928	7,744,643
Total operating expenses	7,710,317	7,405,824	14,142,843	18,282,095
Operating loss	(7,710,317)	(7,405,824)	(14,142,843)	(18,282,095)
Other income (expense):
Other income (expense), net	4,828	8,757	(39,567)	14,442
Interest expense	(204,484)	(335,884)	(363,412)	(1,233,057)
Other income (expense)	(199,656)	(327,127)	(402,979)	(1,218,615)
Loss from continuing operations before provision for income taxes and noncontrolling interests	(7,909,973)	(7,732,951)	(14,545,822)	(19,500,710)
Benefit from income taxes	(5,887,543)	0	(5,887,543)	0
Net loss from continuing operations	(2,022,430)	(7,732,951)	(8,658,279)	(19,500,710)
Discontinued operations - net of taxes	40,487,438	(151,819)	37,329,963	(431,856)
Net income (loss)	38,465,008	(7,884,770)	28,671,684	(19,932,566)
Less - net loss from continuing operations attributable to noncontrolling interests	(54,676)	(63,931)	(119,342)	(127,703)
Less - net (loss) income from discontinued operations attributable to noncontrolling interests	(199,325)	13,877	(568,156)	10,770
Net income (loss) attributable to Caladrius Biosciences, Inc. common stockholders	38,719,009	(7,834,716)	29,359,182	(19,815,633)
Amounts Attributable to Caladrius Inc. common stockholders:
Loss from continuing operations	(1,967,754)	(7,669,020)	(8,538,937)	(19,373,007)
Income (loss) from discontinued operations - net of taxes	40,686,763	(165,696)	37,898,119	(442,626)
Net income (loss) attributable to Caladrius Biosciences, Inc. common stockholders	$ 38,719,009	$ (7,834,716)	$ 29,359,182	$ (19,815,633)
Basic and diluted income (loss) per share
Continuing operations (in usd per share)	$ (0.22)	$ (1.30)	$ (0.99)	$ (3.32)
Discontinued operations (in usd per share)	4.56	(0.03)	4.38	(0.08)
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ 4.34	$ (1.33)	$ 3.39	$ (3.39)
Weighted average common shares outstanding:
Basic and diluted shares	8,926,783	5,907,013	8,657,334	5,839,963

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 38,465,008	$ (7,884,770)	$ 28,671,684	$ (19,932,566)
Available for sale securities - net unrealized loss	(57,860)	(486)	(57,860)	(486)
Total other comprehensive loss	(57,860)	(486)	(57,860)	(486)
Comprehensive income (loss)	38,407,148	(7,885,256)	28,613,824	(19,933,052)
Comprehensive loss attributable to noncontrolling interests	(254,001)	(50,054)	(687,498)	(116,933)
Comprehensive income (loss) attributable to Caladrius Biosciences, Inc. common stockholders	$ 38,661,149	$ (7,835,202)	$ 29,301,322	$ (19,816,119)

Consolidated Statements of Equity - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2015			10,000	5,673,302
Beginning Balance at Dec. 31, 2015	$ 23,283,824	$ 23,713,533	$ 100	$ 5,673	$ 396,547,401	$ 486	$ (372,132,490)	$ (707,637)	$ (429,709)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(19,932,566)	(19,815,633)					(19,815,633)		(116,933)
Unrealized gain/loss on marketable securities	(486)	(486)				(486)
Share-based compensation (in shares)				95,355
Share-based compensation	1,235,144	1,235,144		$ 95	1,235,049
Net proceeds from issuance of common stock (in shares)				158,092
Net proceeds from issuance of common stock	1,050,712	1,050,712		$ 159	1,050,553
Change in Ownership in Subsidiary	0	(133,012)			(133,012)				133,012
Ending Balance at Jun. 30, 2016	5,636,628	6,050,258	$ 100	$ 5,927	398,699,991	0	(391,948,123)	(707,637)	(413,630)
Ending Balance (shares) at Jun. 30, 2016			10,000	5,926,749
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	28,671,684	29,359,182					29,359,182		(687,498)
Unrealized gain/loss on marketable securities	(57,860)	(57,860)				(57,860)
Share-based compensation (in shares)				54,545
Share-based compensation	2,350,652	2,350,652		$ 55	2,350,597
Net proceeds from issuance of common stock (in shares)				648,432
Net proceeds from issuance of common stock	3,278,632	3,278,632		$ 648	3,277,984
Proceeds from option exercises (in shares)				3,835
Proceeds from option exercises	13,576	13,576		$ 4	13,572
Elimination of non-controlling interests associated with PCT sale	(3,686,526)								(3,686,526)
Reclassification of redeemable securities	19,400,000	14,733,908			14,733,908				4,666,092
Change in Ownership in Subsidiary	0	(141,180)			(141,180)				141,180
Ending Balance at Jun. 30, 2017	$ 54,036,638	$ 54,420,819	$ 100	$ 8,913	$ 430,606,930	$ (57,860)	$ (375,429,627)	$ (707,637)	$ (384,181)
Ending Balance (shares) at Jun. 30, 2017			10,000	8,912,602

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 28,671,684	$ (19,932,566)
(Income) loss from discontinued operations	(37,329,963)	431,856
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	1,819,382	883,143
Depreciation and amortization	193,845	252,237
Loss on disposal of assets	175,793	591,307
Accretion on marketable securities	39,175	0
Changes in operating assets and liabilities:
Restricted cash	(5,000,722)	0
Prepaid and other current assets	619,528	405,619
Accounts receivable	(196,872)	(97,904)
Other assets	179,763	147,107
Due to/from PCT	(1,231,258)	2,681,195
Accounts payable, accrued liabilities and other liabilities	(2,879,408)	(2,540,199)
Net cash used in operating activities - continuing operations	(14,939,053)	(17,178,205)
Net cash used in operating activities	(638,069)	2,602,650
Net cash used in operating activities	(15,577,122)	(14,575,555)
Cash flows from investing activities:
Purchase of marketable securities	36,421,971	0
Proceeds from PCT sale	70,264,395	0
Net cash sold in PCT sale	(6,727,263)	0
Acquisition of property, plant and equipment	(97,052)	(1,068,129)
Net cash provided by (used in) investing activities - continuing operations	27,018,109	(1,068,129)
Net cash used in investing activities - discontinued operations	(188,794)	(635,168)
Net cash provided by (used in) investing activities	26,829,315	(1,703,297)
Cash flows from financing activities:
Proceeds from exercise of options	13,576	0
Tax withholding payments on net share settlement equity awards	(357,665)	0
Net proceeds from issuance of common stock	3,278,632	1,050,712
Repayment of long-term debt	(5,651,354)	(6,348,646)
Proceeds from notes payable	400,998	368,615
Repayment of notes payable	(522,313)	(489,925)
PCT dividend to Caladrius	0	15,000,000
Net cash (used in) provided by financing activities - continuing operations	(2,838,126)	9,580,756
Net cash (used in) provided by financing activities - discontinued operations	(74,231)	4,079,371
Net cash (used in) provided by financing activities	(2,912,357)	13,660,127
Net increase (decrease) in cash and cash equivalents	8,339,836	(2,618,725)
Cash and cash equivalents at beginning of period - continuing operations	7,076,651	18,657,971
Cash and cash equivalents at beginning of period - discontinued operations	7,628,357	1,660,440
Cash and cash equivalents at end of period	23,044,844	17,699,686
Less cash and cash equivalents of discontinued operations at end of period	0	7,355,294
Cash and cash equivalents at end of period	23,044,844	10,344,392
Cash paid during the period for:
Interest	$ 697,544	$ 973,729

The Business	6 Months Ended
The Business	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Business	The Business Overview Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”), is a company developing cellular therapeutics to treat certain diseases. We leverage specialized cell therapy clinical development expertise to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in humans. Our current lead product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D"). Immunomodulation (Treg Technology) We are developing strategically, through the utilization of our core clinical development expertise, a product candidate (CLBS03) that is an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells; the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments, only lifelong insulin therapy, which therapy often does not prevent serious co-morbidities. Two Phase 1 clinical trials of this technology in T1D demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis of early therapeutic effect is planned after approximately 50% of patients reach the six-month follow-up milestone, which analysis is expected in late 2017 or early 2018. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA"). Ischemic Repair (CD34 Cell Technology) Our CD34 cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating CLBS12 (a candidate for CLI) was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed with PMDA and, if successful, could provide the basis for conditional approval under Japan's favorable regenerative medicine law. We are seeking to collaborate on CLBS12 with development and/or manufacturing partners. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and expect to learn the results of those applications in 2017. We intend to develop this platform if capital becomes available through grants, partnerships or licensing, as well as potentially using reasonable amounts of our own capital. Additional Out-licensing Opportunities Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product, additional indications for our CD34 cell technology and a platform using tumor cell/dendritic cell technology for immuno-oncology application. The immuno-oncology program has the benefit of promising Phase 2 clinical data and applicability to multiple indications. In 2016, we completed multiple out-licensing agreements for this and other technology platforms in an effort to monetize non-core assets. Our current long-term strategy focuses on advancing cell-based therapies to the market and assisting patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline based on demonstration of proof-of-concept in man as well as process and manufacturing advancements. Discontinued Operations On May 18, 2017 (the "Closing Date"), the Company completed the previously announced sale of its remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement"), dated as of March 16, 2017, by and among Caladrius, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash, plus an additional cash adjustment based on PCT’s cash and outstanding indebtedness as of the Closing Date ("Additional Consideration") and a potential future milestone payment (see Note 3). The sale of PCT represents a strategic shift that has a major effect on the Company’s operations, and therefore, PCT is accounted for as discontinued operations. All periods presented were adjusted to reflect PCT as discontinued operations. Basis of Presentation The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of June 30, 2017 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2016 and 2015 included in our 2016 Form 10-K. Operating results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining useful lives of our long lived assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions. An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application. Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2016 Form 10-K. There were no changes to these policies during the three and six months ended June 30, 2017. Concentration of Risks We are subject to credit risk from our portfolio of cash and cash equivalents, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. Long-Lived Assets Long-lived assets consist of property, plant and equipment. The assets are depreciated on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the three and six months ended June 30, 2017 or June 30, 2016 that would require interim impairment assessment. Recently Issued Accounting Pronouncement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The guidance will be applied prospectively, retrospectively, or by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted, dependent upon the specific amendment that is adopted within the ASU. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

Collaboration and License Agreement

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Collaboration and License Agreement

2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi. This collaboration consists of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi Chemical with certain training and support. As additional consideration, Hitachi Chemical agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of ten years.

2017 Hitachi Transaction

On May 18, 2017, the Company completed the previously announced sale of its remaining 80.1% membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated as of March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing Additional Consideration based on PCT’s cash and outstanding indebtedness as of the Closing Date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”).

Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received an additional $4.4 million cash adjustment payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided for:


•	Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius paid to Dr. Preti $1.9 million (the “First Retention Payment”).

•

As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to $1.9 million for the period from the Closing Date until the date one year after the date of the Closing Date (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”).


•	Dr. Preti will be entitled to 5% of the Milestone Payment if it is successfully earned.

Available-for-Sale-Securities

6 Months Ended

Jun. 30, 2017

Available-for-sale Securities [Abstract]

Available-for-Sale Securities

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2017									December 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	1,489.6	$	—	$	—		$	1,489.6	$	—	$	—	$	—	$	—
Corporate debt securities	46,724.4		—		(57.6		)	46,666.8		—		—		—		—
Money market funds	7,188.6		0.1		—			7,188.7		4,426.8		—		—		4,426.8
Municipal debt securities	75.0		—		—			75.0		—		—		—		—
Sovereign government securities	350.4		—		(0.2		)	350.2		—		—		—		—
Total	$	55,828.0	$	0.1	$	(57.8	)	$	55,770.3	$	4,426.8	$	—	$	—	$	4,426.8

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	June 30, 2017		December 31, 2016
Cash and cash equivalents	$	19,445.3	$	4,426.8
Marketable securities	36,325.0		—
Total	$	55,770.3	$	4,426.8

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	55,828.0	$	55,770.3
Greater than one year	—		—
Total	$	55,828.0	$	55,770.3

Loss Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Loss Per Share

For the three and six months ended June 30, 2017 and 2016, the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At June 30, 2017 and 2016, the Company excluded the following potentially dilutive securities:



	June 30,
	2017	2016
Stock Options	1,119,580	692,205
Warrants	285,462	460,047
Restricted Stock Awards	8,000	70,046
Restricted Stock Units	10,260	—

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June 30, 2017, and December 31, 2016 (in thousands).




	June 30, 2017								December 31, 2016
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	36,325.0	$	—	$	36,325.0	$	—	$	—	$	—	$	—
	$	—	$	36,325.0	$	—	$	36,325.0	$	—	$	—	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Liabilities

6 Months Ended

Jun. 30, 2017

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities as of June 30, 2017 and December 31, 2016 were as follows (in thousands):



	June 30, 2017		December 31, 2016
Salaries, employee benefits and related taxes	$	1,129.6	$	1,406.3
Retention payments	2,233.1		—
Professional fees	192.5		224.5
Income tax payable	6,791.5		—
CIRM upfront funding - current	1,745.5		—
Other	316.4		1,028.6
Total	$	12,408.6	$	2,659.4

Debt	6 Months Ended
Debt	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	Debt Notes Payable As of June 30, 2017 and December 31, 2016, the Company had notes payable of approximately $0.6 million and $0.7 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years. Long-Term Debt On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. In March 2016, concurrent with the 2016 Hitachi Transaction (see Note 3), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Lender, up to a $3.0 million maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 10), the Company repaid $3.0 million of such proceeds to the Lender. The outstanding balance was approximately $5.7 million at December 31, 2016. In May 2017, concurrent with the 2017 Hitachi Transaction (see Note 3), the Company retired the Loan in full, and paid $4.9 million to Lender, comprising principal, interest and early termination fees. The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of 8.50% per annum. During the three and six months ended June 30, 2017, the Company recognized $0.2 million and $0.4 million of interest expense, respectively, related to the Loan and Security Agreement. During the three and six months ended June 30, 2016, the Company recognized $0.3 million and $0.5 million of interest expense, respectively, related to the Loan and Security Agreement.

Redeemable Securities	6 Months Ended
Redeemable Securities	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Redeemable Securities	Redeemable Securities Under the 2016 Hitachi Transaction (see Note 3), Hitachi had the right, at any time following the tenth anniversary of the 2016 Hitachi Transaction to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lesser of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of $19.4 million on March 11, 2016 for its 19.9% ownership interest, plus interest at a rate of 2.0% per annum compounded annually; provided, however, that if Hitachi ownership interests increased subsequent to its initial ownership interest, and it offers to sell its equity holdings in excess of 21% of PCT’s outstanding equity securities, then the Company would be required to purchase all such equity holdings of Hitachi but in no event would the aggregate purchase price of such Hitachi equity holdings exceed $20.5 million plus interest at the rate of 2.0% per annum compounded annually. As of December 31, 2016, since Hitachi had the right to deliver the equity interests in PCT it held in exchange for cash from Caladrius or PCT, the initial $19.4 million value of the non-controlling interest was considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity. Concurrent with 2017 Hitachi Transaction (see Note 3), the Hitachi Put Right was eliminated, and $14.7 million previously classified as Redeemable Securities was classified to Additional Paid in Capital. In addition, the remaining portion classified as Redeemable Securities of $4.7 million was classified to Non-Controlling Interests, representing Hitachi's ownership interest in PCT at the time of the 2016 Hitachi Transaction, which was subsequently eliminated upon the 2017 Hitachi transaction and included the PCT gain on sale.

Shareholders' Equity

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Shareholders' Equity

Reverse Stock Split

On July 28, 2016, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company’s board of directors on July 22, 2016. The Reverse Stock Split became effective on July 27, 2016 at 5:00 pm and the common stock of the Company began trading on The NASDAQ Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of the Company’s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company’s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001.

All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “Additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.

Equity Issuances

September 2016 Registered Direct Offering and Concurrent Private Placement

On September 14, 2016, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of 847,458 shares of the Company’s common stock at a purchase price of $4.72 per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were $4.0 million.

In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a “Private Placement Purchase Agreement” and, collectively, the “Private Placement Purchase Agreements”) with certain accredited investors (the “Investors”) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of 4,449,153 shares of Common Stock, at a purchase price of $4.72 per share. The investments will be placed in two tranches: (i) $12.6 million upon an initial closing (the “Initial Closing”), and (ii) $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). As of March 31, 2017, $6.0 million of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement. This investor had also committed to fund $4.0 million in the Second Closing. As a result, the Company has terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. On March 22, 2017, Sanford Health agreed to waive the conditions for the Second Closing and purchased 423,729 shares of common stock resulting in gross proceeds to the Company of $2.0 million.

Aspire Purchase Agreements

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24-month term. As consideration for entering into the Purchase Agreement, the Company issued 84,270 shares of its common stock to Aspire Capital. During the six months ended June 30, 2017, the Company issued 210,506 shares of common stock under the Purchase Agreement for gross proceeds of $1.2 million. Overall, as of June 30, 2017, the Company has issued 319,776 shares under the Purchase Agreement for gross proceeds of $1.5 million.

Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price, trading volume and conditions, including NASDAQ's trading requirements, are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire Capital at any time, subject to the limitation discussed above.

The Company is party to one other existing agreement with Aspire Capital (the "May 2015 Purchase Agreement"). The registration statement we previously filed with the SEC to cover offerings of shares of our common stock subject to the May 2015 Purchase Agreement has expired, and we have not, and currently have no intention to include such shares in a registration statement filed with the SEC. Unless and until we include such shares in a registration statement filed with the SEC, we are unable to initiate sales to Aspire under the May 2015 Purchase Agreement. Under the May 2015 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares. As consideration for entering into the May 2015 Purchase Agreement, the Company issued 36,484 shares of its common stock to Aspire Capital. The Company has not issued any additional shares under the May 2015 Purchase Agreement.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2017, as adjusted for the Reverse Stock Split:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the period:
Granted	447,157		11.80					—		—
Exercised	(3,835	)	4.70					—		—
Forfeited	(244,413	)	18.70					(1,691	)	700.00
Expired	(32,119	)	37.00					(100,909	)	128.60
Outstanding at June 30, 2017	1,119,580		$	33.50	5.58	$	231.8	285,462		$	57.80	1.10	$	—
Vested at June 30, 2017 or expected to vest in the future	1,119,152		$	33.60	5.58	$	231.8	285,462		$	57.80	1.10	$	—
Vested at June 30, 2017	1,111,740		$	32.90	5.59	$	231.5	285,462		$	57.80	1.10	$	—

Restricted Stock

During the six months ended June 30, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):



	Six Months Ended June 30,
	2017		2016
Number of restricted stock issued	132,726		107,719
Value of restricted stock issued	$	469.9	$	651.7

Share-Based Compensation

6 Months Ended

Jun. 30, 2017

Share-based Compensation [Abstract]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development	$	162.0	$	—	$	208.2	$	71.0
General and administrative	1,261.7		253.5		1,611.2		812.0
Discontinued operations	751.4		82.0		888.9		352.0
Total share-based compensation expense	$	2,175.1	$	335.5	$	2,708.3	$	1,235.0

The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the “Equity Compensation Plans”). Accordingly, all outstanding unvested equity awards were accelerated upon the Closing Date, resulting in an acceleration of $1.9 million of equity compensation for the three and six months ended June 30, 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of $0.3 million, which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at June 30, 2017 were as follows (in thousands):



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	38.8	$	13.6
Expected weighted-average period in years of compensation cost to be recognized	0.69		0.39

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2017 and 2016 were as follows, as adjusted for the Reverse Stock Split (in thousands):



	Stock Options
	Six Months Ended June 30,
	2017		2016
Total fair value of shares vested	$	5,001.7	$	1,153.1
Weighted average estimated fair value of shares granted	$	1.72	$	4.02

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Research Funding	6 Months Ended
Research Funding	Jun. 30, 2017
Research Funding [Abstract]
Research Funding	Research Funding California Institute of Regenerative Medicine Grant Award In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding in May 2017, which will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of June 30, 2017, $1.7 million of the funding received is recorded in Accrued Liabilities, representing the amount expected to be recognized over the next 12 months, and $3.6 million of the funding received is recorded in Other Long-Term Liabilities. During the three months ended June 30, 2017, the Company amortized and recognized a $0.3 million credit to research and development related to CIRM funds received.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes As of December 31, 2016, the Company had approximately $232.7 million of federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2027 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur, there would be an annual limitation on the usage of the Company’s losses which are available through 2036. In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. During the quarter ended June 30, 2017, the Company generated a gain from the sale of 80.1% of their ownership in PCT. The gain from the sale of PCT is included in discontinued operations. The Company for the six months ended June 30, 2017 has generated losses from continuing operations and has forecasted losses for the remainder of the year. Based on generating taxable income for the 2017 year, the Company will utilize net operating losses which were offset by a full valuation allowance. The Company anticipates that they will maintain a valuation allowance on the remaining deferred tax assets at the end of the year. Deferred tax liabilities were $0 and $1.1 million as of June 30, 2017 and December 31, 2016, respectively, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011. The taxable temporary differences, which were tax deductible and were to be amortized over 15 years. The deferred tax liability was reversed during the three months ended June 30, 2017, as a result of the divestiture of PCT. The Company applies ASC 740-10 for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense. As of June 30, 2017, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. During the second quarter the Company has both continuing and discontinued operations. ASC 740-20-45-7 addresses the income tax accounting treatment when there is a loss from continuing operations and income from discontinuing operations. The Company must consider the gain from discontinued operations for purposes of allocating a tax benefit to the current year loss from continuing operations. The Company has adopted a method in which the income from discontinued operations are recognized as a discrete item in the period in which it occurs and apply the concepts of the annual effective tax rate (AETR) during each period in computing the income tax provision from continuing operations. This method results in a tax expense for discontinued operations and an income tax benefit for the loss generated from continuing operations. The Company is forecasting losses from continuing operations for the remainder of 2017 against which an income tax benefit will be recorded. The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The foreign returns filed for 2012 and prior are subject to examination for five years.

Discontinued Operations

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

PCT Segment

On May 18, 2017, the Company completed the previously announced Sale of its remaining 80.1% membership interest in PCT to Hitachi. Pursuant to the Purchase Agreement, by and among Caladrius, PCT and Hitachi, the aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) a cash adjustment, based on PCT’s cash and outstanding indebtedness as of the Closing Date, of approximately $4.4 million, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in Cumulative Revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”). The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero.

Pursuant to the terms of the Purchase Agreement, Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions included in the Purchase Agreement. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the additional $4.4 million cash adjustment payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the Sale, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the Closing Date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts Receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT	$	51,744

The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the three and six months ended June 30, 2017 and June 30, 2016 were as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	5,729		$	10,002		$	16,039		$	19,116
Cost of revenues	(5,268		)	(8,125		)	(15,321		)	(15,640		)
Research and development	(143		)	(168		)	(257		)	(333		)
Selling, general, and administrative	(8		)	(1,789		)	(3,251		)	(3,420		)
Other expense	(8		)	(26		)	(16		)	(55		)
Provision for income taxes	(11,559		)	(47		)	(11,608		)	(100		)
Gain on sale of segment	51,744			—			51,744			—
Income (loss) from discontinued operations	$	40,487		$	(152	)	$	37,330		$	(432	)

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Lease Commitments

We lease facilities under various operating lease agreements in Basking Ridge, NJ, New York, NY, and Irvine, CA, of which certain leases have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2017 are as follows (in thousands):



Years ended	Operating Leases
2017	$	655.1
2018	817.4
2019	786.2
2020	801.6
2021 and thereafter	603.0
Total minimum lease payments	$	3,663.3

Expense incurred under operating leases was approximately $0.4 million and $0.7 million for the three and six months ended June 30, 2017, respectively. Expense incurred under operating leases was approximately $0.3 million and $0.7 million for the three and six months ended June 30, 2016, respectively.

Contingencies

We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first 19 enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining 92 patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2017
Accounting Policies [Abstract]
Concentration of Risks	Concentration of Risks We are subject to credit risk from our portfolio of cash and cash equivalents, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Share-Based Compensation	Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Long-Lived Assets	Long-Lived Assets Long-lived assets consist of property, plant and equipment. The assets are depreciated on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the three and six months ended June 30, 2017 or June 30, 2016 that would require interim impairment assessment.
Recently Issued Accounting Pronouncement	Recently Issued Accounting Pronouncement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The guidance will be applied prospectively, retrospectively, or by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted, dependent upon the specific amendment that is adopted within the ASU. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

Available-for-Sale-Securities (Tables)

6 Months Ended

Jun. 30, 2017

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2017									December 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	1,489.6	$	—	$	—		$	1,489.6	$	—	$	—	$	—	$	—
Corporate debt securities	46,724.4		—		(57.6		)	46,666.8		—		—		—		—
Money market funds	7,188.6		0.1		—			7,188.7		4,426.8		—		—		4,426.8
Municipal debt securities	75.0		—		—			75.0		—		—		—		—
Sovereign government securities	350.4		—		(0.2		)	350.2		—		—		—		—
Total	$	55,828.0	$	0.1	$	(57.8	)	$	55,770.3	$	4,426.8	$	—	$	—	$	4,426.8

Schedule of Marketable Securities



	June 30, 2017		December 31, 2016
Cash and cash equivalents	$	19,445.3	$	4,426.8
Marketable securities	36,325.0		—
Total	$	55,770.3	$	4,426.8

Investments Classified by Contractual Maturity Date

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	55,828.0	$	55,770.3
Greater than one year	—		—
Total	$	55,828.0	$	55,770.3

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

At June 30, 2017 and 2016, the Company excluded the following potentially dilutive securities:



	June 30,
	2017	2016
Stock Options	1,119,580	692,205
Warrants	285,462	460,047
Restricted Stock Awards	8,000	70,046
Restricted Stock Units	10,260	—

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis




	June 30, 2017								December 31, 2016
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	36,325.0	$	—	$	36,325.0	$	—	$	—	$	—	$	—
	$	—	$	36,325.0	$	—	$	36,325.0	$	—	$	—	$	—	$	—

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities as of June 30, 2017 and December 31, 2016 were as follows (in thousands):



	June 30, 2017		December 31, 2016
Salaries, employee benefits and related taxes	$	1,129.6	$	1,406.3
Retention payments	2,233.1		—
Professional fees	192.5		224.5
Income tax payable	6,791.5		—
CIRM upfront funding - current	1,745.5		—
Other	316.4		1,028.6
Total	$	12,408.6	$	2,659.4

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Share-based Compensation, Stock Options, Activity

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2017, as adjusted for the Reverse Stock Split:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the period:
Granted	447,157		11.80					—		—
Exercised	(3,835	)	4.70					—		—
Forfeited	(244,413	)	18.70					(1,691	)	700.00
Expired	(32,119	)	37.00					(100,909	)	128.60
Outstanding at June 30, 2017	1,119,580		$	33.50	5.58	$	231.8	285,462		$	57.80	1.10	$	—
Vested at June 30, 2017 or expected to vest in the future	1,119,152		$	33.60	5.58	$	231.8	285,462		$	57.80	1.10	$	—
Vested at June 30, 2017	1,111,740		$	32.90	5.59	$	231.5	285,462		$	57.80	1.10	$	—

Schedule of Restricted Stock

During the six months ended June 30, 2017 and 2016, the Company issued restricted stock for services as follows (in thousands, except share data):



	Six Months Ended June 30,
	2017		2016
Number of restricted stock issued	132,726		107,719
Value of restricted stock issued	$	469.9	$	651.7

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development	$	162.0	$	—	$	208.2	$	71.0
General and administrative	1,261.7		253.5		1,611.2		812.0
Discontinued operations	751.4		82.0		888.9		352.0
Total share-based compensation expense	$	2,175.1	$	335.5	$	2,708.3	$	1,235.0

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	38.8	$	13.6
Expected weighted-average period in years of compensation cost to be recognized	0.69		0.39

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value



	Stock Options
	Six Months Ended June 30,
	2017		2016
Total fair value of shares vested	$	5,001.7	$	1,153.1
Weighted average estimated fair value of shares granted	$	1.72	$	4.02

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts Receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT	$	51,744



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	5,729		$	10,002		$	16,039		$	19,116
Cost of revenues	(5,268		)	(8,125		)	(15,321		)	(15,640		)
Research and development	(143		)	(168		)	(257		)	(333		)
Selling, general, and administrative	(8		)	(1,789		)	(3,251		)	(3,420		)
Other expense	(8		)	(26		)	(16		)	(55		)
Provision for income taxes	(11,559		)	(47		)	(11,608		)	(100		)
Gain on sale of segment	51,744			—			51,744			—
Income (loss) from discontinued operations	$	40,487		$	(152	)	$	37,330		$	(432	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2017 are as follows (in thousands):



Years ended	Operating Leases
2017	$	655.1
2018	817.4
2019	786.2
2020	801.6
2021 and thereafter	603.0
Total minimum lease payments	$	3,663.3

The Business Immunomodulation (Treg Technology) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 cohort	May 04, 2017 USD ($)	Feb. 23, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Interim Efficacy Analysis, Percentage Threshold	50.00%
Interim Efficacy Analysis, Follow-up Milestone Period	6 years
Grants Receivable			$ 12.2
Grants Receivable, Current		$ 5.7
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of Cohorts \| cohort	2

Collaboration and License Agreement (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	May 18, 2017	Jul. 31, 2017	Mar. 31, 2017	Jun. 30, 2017	Sep. 30, 2016	May 18, 2018	Mar. 11, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage							19.90%
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage							21.00%
Recorded Unconditional Purchase Obligation							$ 19,400
Unrecorded Unconditional Purchase Obligation, Maximum Quantity							15,000
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Contract Receivable							$ 5,600
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Purchase Obligation							$ 4,400
Minimum [Member] \| PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Length of Contract for Royalty Payments from Revenue Generated in Asia					10 years
Director [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment	$ 1,900
Director [Member] \| Scenario, Forecast [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment						$ 1,900
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment						5.00%
Discontinued Operations [Member] \| PCT Segment [Member]
Business Acquisition [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Transaction Costs Related to Sale	$ 6,919
Payments to Employees				$ (4,300)
Retention Payments, First Retention Payment, Percent				50.00%
Retention Payments, Second Retention Payment, Percent				50.00%
Discontinued Operations [Member] \| PCT Segment [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Purchase Agreement, Additional Consideration	4,400
Purchase Agreement, Potential Future Milestone Payment	5,000
Cumulative Revenue Threshold for Receiving Milestone Payment	125,000
Proceeds From Licensing Agreements, Initial Payment			$ 5,000
Proceeds From Licensing Agreements, Closing Payments	65,000
Proceeds From Licensing Agreements, Escrow Amount	5,000
Discontinued Operations [Member] \| PCT Segment [Member] \| PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Purchase Agreement, Aggregate Purchase Price	$ 75,000
Discontinued Operations [Member] \| PCT Segment [Member] \| Subsequent Event [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Proceeds From Licensing Agreements, Closing Payments		$ 4,400

Available-for-Sale-Securities Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 55,828,000	$ 4,426,800
Gross Unrealized Gains	100	0
Gross Unrealized Losses	(57,800)	0
Estimated Fair Value	55,770,300	4,426,800
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,489,600	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	1,489,600	0
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	46,724,400	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(57,600)	0
Estimated Fair Value	46,666,800	0
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	7,188,600	4,426,800
Gross Unrealized Gains	100	0
Gross Unrealized Losses	0	0
Estimated Fair Value	7,188,700	4,426,800
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	75,000	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	75,000	0
US Government Agencies Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	350,400	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(200)	0
Estimated Fair Value	$ 350,200	$ 0

Available-for-Sale-Securities Classification of Available-for-Sale Securities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Available-for-sale Securities [Abstract]
Cash and cash equivalents	$ 19,445,300	$ 4,426,800
Marketable securities	36,324,936	0
Total	$ 55,770,300	$ 4,426,800

Available-for-Sale-Securities Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Amortized Cost
Less than one year	$ 55,828,000
Greater than one year	0
Amortized Cost, Total	55,828,000
Estimated Fair Value
Less than one year	55,770,300
Greater than one year	0
Estimated Fair Value, Total	$ 55,770,300	$ 4,426,800

Loss Per Share (Details) - shares	6 Months Ended
Loss Per Share (Details) - shares	Jun. 30, 2017	Jun. 30, 2016
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	1,119,580	692,205
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	285,462	460,047
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	8,000	70,046
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	10,260	0

Fair Value Measurements Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	$ 36,325,000	$ 0
Assets, fair value disclosure	36,325,000	0
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0
Assets, fair value disclosure	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	36,325,000	0
Assets, fair value disclosure	36,325,000	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0
Assets, fair value disclosure	$ 0	$ 0

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

Accrued Liabilities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,129,600	$ 1,406,300
Retention payments	2,233,100	0
Professional fees	192,500	224,500
Income tax payable	6,791,500	0
CIRM upfront funding - current	1,745,500	0
Other	316,400	1,028,600
Total accrued liabilities	$ 12,408,600	$ 2,659,400

Debt (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
Debt (Details) - USD ($)	May 18, 2017	Sep. 14, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable				$ 600,000		$ 600,000		$ 700,000
Interest Expense				$ 204,484	$ 335,884	$ 363,412	$ 1,233,057
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Interest Expense					$ 300,000		$ 500,000
Notes Payable, Other Payables [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms						1 year
Notes Payable, Other Payables [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms						3 years
Oxford Finance LLC [Member] \| Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross									$ 15,000,000
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent			20.00%
Oxford Finance LLC [Member] \| Loan and Security Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Amount			$ 3,000,000
Oxford Finance LLC [Member] \| Loans Payable [Member] \| Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Repayments of Debt	$ 4,900,000	$ 3,000,000	$ 7,000,000
Long-term Debt								$ 5,700,000
Debt Instrument, Interest Rate, Effective Percentage				8.50%		8.50%

Redeemable Securities (Details) - USD ($) $ in Millions	May 18, 2017	Mar. 11, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage		19.90%
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Recorded Unconditional Purchase Obligation		$ 19.4
Equity Method Investment, Ownership Percentage		21.00%
Business Combination, Consideration Transfered, Interest Rate		2.00%
Redeemable Securities Agreement, Required Purchase Based on Equity Event, Maximum		$ 20.5
Redeemable Securities, Classified to Additional Paid In Capital	$ 14.7
Redeemable Securities, Classified to Non-Controlling Interests	$ 4.7

Shareholders' Equity - Reverse Stock Split (Details)	Jul. 28, 2016 $ / shares	Jun. 30, 2017 $ / shares	Dec. 31, 2016 $ / shares
Equity [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001	$ 0.001
Reverse Stock Split, Conversion Ratio	0.1

Shareholders' Equity - Equity Issuances (Details) $ / shares in Units, $ in Millions			1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 22, 2017 USD ($) shares	Sep. 14, 2016 USD ($) clinical_trial_subject $ / shares shares	Nov. 30, 2015 USD ($) shares	Mar. 31, 2017 USD ($)	Jun. 30, 2017 USD ($) shares	Dec. 31, 2016 shares	May 31, 2015 shares	May 01, 2015 USD ($)
Class of Stock [Line Items]
Common Stock Warrants, Shares \| shares					285,462	388,062
Shares Issued, Price Per Share \| $ / shares		$ 4.72
Common stock, shares issued \| shares					8,912,602	8,205,791
RD Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	423,729	847,458
Proceeds from Issuance of Common Stock	$ 2.0	$ 4.0
Private Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock				$ 6.0
Proceeds from Issuance of Common Stock, Second Closing, Receivable				$ 4.0
Purchase Commitment, Maximum Amount Committed, Shares \| shares		4,449,153
Proceeds from Issuance of Common Stock, Initial Closing		$ 12.6
Proceeds from Issuance of Common Stock, Second Closing		$ 8.4
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing \| clinical_trial_subject		70
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock					$ 1.2
Purchase Commitment, Maximum Amount Committed, Shares \| shares			1,101,927.6
Purchase Commitment, Remaining Minimum Amount Committed			$ 30.0
Term of agreement in months			24 months
Stock Issued During Period, Shares, Other \| shares			84,269.6		210,506
Shares, Issued \| shares					319,776
Common Stock, Value, Issued					$ 1.5
Discount Applied To Weighted Average Price			5.00%
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase Commitment, Remaining Minimum Amount Committed								$ 30.0
Common stock, shares issued \| shares							36,483.7

Shareholders' Equity - Stock options and warrants (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2017 USD ($) $ / shares $ / warrant shares	Dec. 31, 2016 USD ($) $ / shares $ / warrant shares
Warrants, Number of Shares [Roll Forward]
Warrants, Shares, Beginning of Period	388,062
Warrants Granted	0
Warrants Exercised	0
Warrants Canceled	(1,691)
Warrants Expired	(100,909)
Warrants, Shares, End of Period	285,462	388,062
Warrants Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Warrants Outstanding, Beginning of Period \| $ / warrant	76.50
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0.00
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	0.00
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	700.00
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 128.60
Weighted Average Exercise Price, Warrants Outstanding, End of Period \| $ / warrant	57.80	76.50
Weighted Average Remaining Contractual Term, Warrant outstanding	1 year 1 month 6 days	1 year 2 months 27 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 0
Warrants, vested and expected to vest	285,462
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	57.80
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 1 month 6 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Warrants, Vested. Number	285,462
Warrants, Vested, Weighted Average Exercise Price \| $ / warrant	57.80
Warrants, Vested, Weighted Average Remaining Contractual Term	1 year 1 month 6 days
Warrants, Vested, Aggregate Intrinsic Value \| $	$ 0
US Equity Plan [Member]
Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning of Period	952,790
Options, Grants in Period, Net of Forfeitures	447,157
Options, Exercises in Period	(3,835)
Options, Forfeitures in Period	(244,413)
Options, Expirations in Period	(32,119)
Options, Outstanding, End of Period	1,119,580	952,790
Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period \| $ / shares	$ 39.90
Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	11.80
Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	4.70
Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	18.70
Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	37.00
Options, Outstanding, Weighted Average Exercise Price, End of Period \| $ / shares	$ 33.50	$ 39.90
Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months 29 days	7 years 7 months 6 days
Options, Outstanding, Intrinsic Value \| $	$ 231,800	$ 0
Options, Vested and Expected to Vest, Outstanding, Number	1,119,152
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 33.60
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months 29 days
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 231,800
Options, Vested and Expected to Vest, Exercisable, Number	1,111,740
Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 32.90
Options, Vested, Weighted Average Remaining Contractual Term	5 years 7 months 2 days
Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 231,500

Shareholders' Equity - Restricted Stock (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Equity [Abstract]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	132,726	107,719
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 469,900	$ 651,700

Share-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
Share-Based Compensation (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 2,175,100	$ 335,500	$ 2,708,300	$ 1,235,000
Accelerated equity compensation cost	1,900,000		1,900,000
Modification incremental compensation cost	300,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 38,800		$ 38,800
Expected weighted-average period in years of compensation cost to be recognized			8 months 9 days
Total fair value of shares vested			$ 5,001,700	$ 1,153,100
Weighted average estimated fair value of shares granted	$ 1.72	$ 4.02	$ 1.72	$ 4.02
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 13,600		$ 13,600
Expected weighted-average period in years of compensation cost to be recognized			4 months 21 days
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	162,000	$ 0	$ 208,200	$ 71,000
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	1,261,700	253,500	1,611,200	812,000
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 751,400	$ 82,000	$ 888,900	$ 352,000

Research Funding (Details) - USD ($) $ in Millions	3 Months Ended
Research Funding (Details) - USD ($) $ in Millions	Jun. 30, 2017	May 04, 2017	Feb. 23, 2017
Deferred Revenue Arrangement [Line Items]
Grants Receivable			$ 12.2
Grants Receivable, Current		$ 5.7
Grant Revenue Recognized	$ 0.3
Accrued Liabilities [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Grant Revenue	1.7
Other Long-Term Liabilities [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Grant Revenue	$ 3.6

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 232.7
Deferred Tax Liabilities, Net, Noncurrent	$ 0.0	$ 1.1

Discontinued Operations PCT Segment Narrative (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
	May 18, 2017	Jul. 31, 2017	Mar. 31, 2017	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Transaction Costs Related to Sale	$ 6,919
Payments to Employees				$ 4,300
Retention Payments, First Retention Payment, Percent				50.00%
Retention Payments, Second Retention Payment, Percent				50.00%
Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Agreement, Additional Consideration	4,400
Purchase Agreement, Potential Future Milestone Payment	5,000
Cumulative Revenue Threshold for Receiving Milestone Payment	125,000
Proceeds From Licensing Agreements, Initial Payment			$ 5,000
Proceeds From Licensing Agreements, Closing Payments	65,000
Proceeds From Licensing Agreements, Escrow Amount	5,000
PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Agreement, Aggregate Purchase Price	$ 75,000
Subsequent Event [Member] \| Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds From Licensing Agreements, Closing Payments		$ 4,400

Discontinued Operations Gain on Sale of Discontinued Operation (Details) - USD ($)		3 Months Ended		6 Months Ended
	May 18, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Less carrying amount of assets and liabilities sold:
Cash		$ 0	$ 7,355,294	$ 0	$ 7,355,294	$ 7,628,357	$ 1,660,440
PCT Segment [Member] \| Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of consideration received	$ 79,425,000
Transaction and retention costs	6,919,000
Carrying value of segment non-controlling interest	3,687,000
Total consideration net of transaction costs and adjustments	76,193,000
Less carrying amount of assets and liabilities sold:
Cash	6,727,000
Accounts Receivable	3,702,000
Deferred costs	4,685,000
Prepaid expenses and other current assets	743,000
Property, plant and equipment, net	14,900,000
Goodwill	7,013,000
Intangibles, net	2,090,000
Other assets	215,000
Accounts payable	2,278,000
Accrued liabilities	2,927,000
Due from Caladrius	450,000
Unearned revenues	10,529,000
Notes payable	342,000
Disposal group, including discontinued operation, net assets	24,449,000
Gain on sale of PCT	$ 51,744,000	$ 51,744,000	$ 0	$ 51,744,000	$ 0

Discontinued Operations Operating Results of PCT Segment (Details) - USD ($)		3 Months Ended		6 Months Ended
	May 18, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations		$ 40,487,438	$ (151,819)	$ 37,329,963	$ (431,856)
PCT Segment [Member] \| Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		5,729,000	10,002,000	16,039,000	19,116,000
Cost of revenues		(5,268,000)	(8,125,000)	(15,321,000)	(15,640,000)
Research and development		(143,000)	(168,000)	(257,000)	(333,000)
Selling, general, and administrative		(8,000)	(1,789,000)	(3,251,000)	(3,420,000)
Other expense		(8,000)	(26,000)	(16,000)	(55,000)
Provision for income taxes		(11,559,000)	(47,000)	(11,608,000)	(100,000)
Gain on sale of segment	$ 51,744,000	51,744,000	0	51,744,000	0
Income (loss) from discontinued operations		$ 40,487,000	$ (152,000)	$ 37,330,000	$ (432,000)

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
2017	$ 655,100		$ 655,100
2018	817,400		817,400
2019	786,200		786,200
2020	801,600		801,600
2021 and thereafter	603,000		603,000
Total minimum lease payments	3,663,300		3,663,300
Operating lease expense	$ 400,000	$ 300,000	$ 700,000	$ 700,000